Von hippel lindau syndrome

Advances in Experimental Medicine and Biology

Volumn 685, Issue , 2010, Pages 228-249

  Kim, Jenny J ^b   Rini, Brian I ^b   Hansel, Donna E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BETA CATENIN; BEVACIZUMAB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PAZOPANIB; PROTEIN P53; RANIBIZUMAB; SORAFENIB; SUNITINIB; UVOMORULIN; VANDETANIB; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; BREAST CANCER; CANCER SURGERY; CHROMOSOME 3; CLINICAL FEATURE; COLON CANCER; DNA DAMAGE; EAR TUMOR; ENDOLYMPHATIC SAC; EPIDIDYMAL CYST; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENETIC LINKAGE; GERM LINE; HEMANGIOBLASTOMA; HUMAN; INCIDENCE; KIDNEY CARCINOMA; KIDNEY CYST; LUNG CANCER; MOLECULAR GENETICS; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS TUMOR; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; RADIOTHERAPY; STEREOTACTIC TREATMENT; TRANSACTIVATION; TUMOR SUPPRESSOR GENE; VHL GENE; VON HIPPEL LINDAU DISEASE; AGE; FAMILIAL CANCER; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PENETRANCE; REVIEW; VASCULAR TUMOR;

AGE FACTORS; GERM-LINE MUTATION; HUMANS; INCIDENCE; NEOPLASTIC SYNDROMES, HEREDITARY; PENETRANCE; VASCULAR NEOPLASMS; VON HIPPEL-LINDAU DISEASE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 77955889110     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6448-9_22     Document Type: Article

References (191)

1. Collins E. Intraocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes). Trans Ophthalmol Soc UK 1894; 14:141-149.
2. Hippel Ev. Ueber eine sehr seltene erkrankung der nethat. Graefe Arch Ophthalmol 1904; 59:83-106.
3. Lindau A. Zur frage der angiomatosis retinai und ihrer hirncomplikation. Acta Ophthalmol 1927; 4:193-226.
4. Davison C, Brock S, Cyke CG. Retinal and central nervous hemangioblastomatosis with visceral changes (von Hippel-Lindau's disease). Bull Neurol Inst New York 1936; 5:72-93.
5. Glushien AS, Mansuy MM, Littman DS. Pheochromocytoma. Its relationship to the neurocutaneous syndrome. AM J Med 1953; 14:318-27.
6. Melmon KL, Rosen SW. Lindau's disease: Review of the literature and study of a large kindred. Am J Med 1964; 36:595-617.
7. Manski TJ, Heffner DK, Glenn GM et al. Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel Lindau disease. J Am Med Assoc 1997; 277:1461-1466. (Pubitemid 27208889)
8. Maher ER, Kaelin WG Jr. von Hippel-Lindau disease. Medicine 1997; 76:381-391. (Pubitemid 28016534)
9. Seizinger BR et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988; 332:268-269. (Pubitemid 18076658)
10. Latif F et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260:1317-1320. (Pubitemid 23231974)
11. Woodward E et al. Comparative sequence analysis of the VHL tumor suppressor gene. Genomics 2000; 65:253-265. (Pubitemid 30332029)
12. Chen F et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Hum Mutat 1995; 5:66-75.
13. Zbar B et al. Germline mutations in the von Hipple-Lindau (VHL) gene in families from North America, Europe and Japan. Hum Mutat 1996; 8:348-357. (Pubitemid 26412151)
14. Neumann H, Bender B. Genotype-phenotype correlations in von Hipple-Lindau disease. J Intern Med 1998; 243:541-545. (Pubitemid 28312254)
15. Knudson AGJ, Strong LC. Mutation and cancer: Neuroblastoma and pheochromocytoma. Am J Hum Genet 1972; 24:514-532.
16. Knudson AGJ. Genetics of human cancer. Ann Rev Genet 1986; 20:231-251.
17. Kanno H, Kondo K, Ito S et al. Somatic mutations of the von Hippel-Lindau tumour suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 1994; 54:4845-47. (Pubitemid 24289412)
18. Lee JY, Dong SM, Park WS et al. Loss of heterozygosity and somatic mutations of the VHL tumour suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res 1998; 58:504-08.
19. Oberstrass J, Reifenberger G, Reifenberger J et al. Mutation of the Von Hippel-Lindau tumour suppressor gene in capillary haemangioblastomas of the central nervous system. J Pathol 1996; 179:151-56. (Pubitemid 26201582)
20. Tse JY, Wong JH, Lo KW et al. Molecular genetic analysis of the von Hippel-Lindau disease tumour suppressor gene in familial and sporadic cerebellar hemangioblastomas. Am J Clin Pathol 1997; 107:459-66. (Pubitemid 27147076)
21. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7:85-90. (Pubitemid 24232386)
22. Shuin T et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994; 54:2852-2855.
23. Foster K et al. Somatic mutations of the von Hippel-Lindau disease tumor suppressor gene in nonfamilial clear cell renal carcinoma. Hum Mol Genet 1994; 3:2169-2173.
24. Kondo K, Yao M, Yoshida M et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002; 34:58-68. (Pubitemid 34260597)
25. Herman JG et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91:9700-9704. (Pubitemid 24311875)
26. Her C, Wu X, Griswold MD et al. MutS Homologue MSH4 Physically Interacts with von Hippel-Lindau Tumor Suppressor-binding Protein 1. Cancer Research 2003; 63:865-872. (Pubitemid 36231989)
27. Tsuchiya H, Tokuhiro I, Hino O. Identification of a Novel Protein (VBP-1) Binding to the von Hippel-Lindau (VHL) Tumor Suppressor Gene Product. Cancer Research 1996; 56:2881-2885.
28. Brinke A, Green PM, Giannelli F. Characterization of the Gene (VBP1) and Transcript for the von Hippel-Lindau Binding Protein and Isolation of the Highly Conserved Murine Homologue. Genomics 1997; 45:105-112. (Pubitemid 27449389)
29. Geissler S, Siegers K, Schiebel E. A novel protein complex promoting formation of functionaland -tubulin. EMBO J 1998; 17:952-966. (Pubitemid 28077650)
30. Vainberg IE, Lewis SA, Rommelaere H et al. Prefoldin, a chaperone that delivers unfolded proteins to cytosolic chaperonin. Cell 1998; 93:863-873. (Pubitemid 28257591)
31. Alvarez P, Smith A, Fleming J et al. Modulation of tubulin polypeptide ratios by the yeast protein Pac10p. Genetics 1998; 149:857-864. (Pubitemid 28283165)
32. Kneitz B, Cohen PE, Avdievich E et al. MutS homolog 4 localization to meiotic chromosomes is required for chromosome pairing during meiosis in male and female mice. Genes Dev 2000; 14:1085-1097. (Pubitemid 30324422)
33. Edelmann W, Cohen PE, Kneitz B et al. Mammalian MutS homologue 5 is required for chromosome pairing in meiosis. Nat Genet 1999; 21:123-127. (Pubitemid 29036298)
34. De Vries SS, Baart EB, Dekker M et al. Mouse MutS-like protein Msh5 is required for proper chromosome synapsis in male and female meiosis. Genes Dev 1999; 13:523-531. (Pubitemid 29131877)
35. Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399:271-275. (Pubitemid 29246458)
36. Tanimoto K, Makino Y, Pereira T et al. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000; 19:4298-4309. (Pubitemid 30623741)
37. Kamura T, Sato S, Iwai K et al. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000; 97:10430-10435.
38. Bardos JI, Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 2004; 26:262-269. (Pubitemid 38325667)
39. Gordan JD, Simon MC. Hypoxia-inducible factors: Central regulators of the tumor phenotype. Curr Opin Genet Dev 2007; 17:71-77. (Pubitemid 46109295)
40. Hoffman MA, Ohh M, Yang H et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 2001; 10:1019-1027. (Pubitemid 32447779)
41. Knauth K, Bex C, Jemth P et al. Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions. Oncogene 2006; 25:370-377. (Pubitemid 43117622)
42. Pause A et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 1997; 94:2156-2161. (Pubitemid 27136844)
43. Pause A, Peterson B, Schaffar G et al. Studying interactions of four proteins in the yeast two-hybrid system: Structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein. Proc Natl Acad Sci USA 1999; 96:9533-9538. (Pubitemid 29398765)
44. Bai C et al. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 1996; 86:263-274.
45. Deshaies R. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 1999; 15:435-467. (Pubitemid 32250383)
46. Stebbins CE, Kaelin WG, Pavletich NP. Structure of the VHL-elongin-C-elongin-B complex: Implications for VHL tumor suppressor function. Science 1999; 284:455-461. (Pubitemid 29289612)
47. Lisztwan J, Imbert G, Wirbelauer C et al. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 1999; 13:1822-1833. (Pubitemid 29353049)
48. Iwai K et al. Identification of the von Hippel-Lindau tumor suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 1999; 96:12436-12441. (Pubitemid 29513520)
49. Kamura T et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999; 284:657-661. (Pubitemid 29289593)
50. Los M et al. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest 1996; 75:231-238. (Pubitemid 26272361)
51. Lee S et al. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol 1999; 19:1486-1497.
52. Schoenfeld A, Davidowitz E, Burk R. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci USA 1998; 95:8817-8822. (Pubitemid 28350572)
53. Iliopoulos O, Ohh M, Kaelin W. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 1998; 95:11661-11666.
54. Blankenship C, Naglich J, Whaley J et al. Alternate choice of initiation codon produces a biologically active product of the von Hippel-Lindau gene with tumor suppressor activity. Oncogene 1999; 18:1529-1535. (Pubitemid 29108052)
55. Semenza G. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999; 15:551-578. (Pubitemid 32250386)
56. Stadler W. Chromosomes, hypoxia, angiogenesis and trial design: A brief history of renal cancer drug development. Clin Cancer Res 2007; 13:1630-1633. (Pubitemid 46952926)
57. Wang GL, Semenza GL. General involvement of hypoxia inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993; 90:4304-4308. (Pubitemid 23134215)
58. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001; 13:167-171. (Pubitemid 32209217)
59. Iliopoulos O, Levy AP, Jiang C et al. Negative regulation of hypoxia-inudcible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996; 93:10595-105599.
60. Ivan M, Kondo K, Yang H et al. HIF-alpha targeted for VHL-mediated destruction by praline hydroxylation: Implications for O2 sensing. Science 2001; 292:464-468. (Pubitemid 32335941)
61. Jaakkola P, Mole DR, Tian YM et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292:468-472. (Pubitemid 32335942)
62. Yu F, White SB, Zhao Q et al. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA 2001; 98:9630-9635. (Pubitemid 32769354)
63. Papandreou I, Cairns RA, Fontana L et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006; 3:187-197.
64. Kim JW, Tchernyshyov I, Semenza GL et al. HIF-1 mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adpaptation to hypoxia. Cell Metab 2006; 3:177-185.
65. Levy AP, Levy NS, Iliopoulos O et al. Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene. Kidney Int 1997; 51:575-578. (Pubitemid 27088179)
66. Petrella BL, Lohi J, Brinckerhoff CE. Identification of membrane type-1 matrix metalloproteinase as a taret of hypoxia-inducible factor-2+ in von Hippel-Lindau renal cell carcinioma. Oncogene 2005; 24:1043-1052. (Pubitemid 40313881)
67. Erler JT et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440:1222-1226.
68. Staller P et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003; 425:307-311. (Pubitemid 37158407)
69. Zagzag D et al. Stromal cell-derived factor-1+ and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: Von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 2005; 65:6178-6188. (Pubitemid 40994403)
70. Knebelmann B, Ananth S, Cohen HT et al. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 1998; 58:226-231. (Pubitemid 28047059)
71. Franovic A et al. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its expression in human cancer. Prox Natl Acad Sci USA 2007; 104:13092-13097. (Pubitemid 351737598)
72. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2:673-682. (Pubitemid 37328918)
73. Sowter HM, Raval R, Moore J et al. Predominant Role of Hypoxia-Inducible Transcription Factor (HIF)-1 versus HIF-2 in Regulation of the Transcriptional Response to Hypoxia1. Cancer Research 2003; 63:6130-6134. (Pubitemid 37255150)
74. Wiesener MS, Turley H, Allen WE et al. Induction of endothelial PAS domain protein-1 by hypoxia: Characterization and comparison with hypoxia-inducible factor-1. Blood 1998; 92:2260-2268. (Pubitemid 28452966)
75. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: Sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007; 12(2):108-13. (Pubitemid 47199124)
76. Hu CJ, Wang LY, Chodosh LA et al. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 2003; 23:9361-9374. (Pubitemid 37499822)
77. Huang LE, Bindra RS, Glazer PM et al. Hypoxia-induced genetic instability-a calculated mechanism underlying tumor progression. J Mol Med 2007; 85:139-148. (Pubitemid 46188219)
78. Kim JW, Tchernyshyov I, Semenza GL et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3:177-185.
79. Lum JJ, Bui T, Gruber M et al. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev 2007; 21:1037-1049. (Pubitemid 46686473)
80. Papandreou I, Cairns RA, Fontana L et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006; 3:187-197.
81. Ema M, Hirota K, Mimura J et al. Molecular mechanisms of transcription activation by HLF and HIF1 in response to hypoxia: Their stabilisation and redox signal-induced interaction with CBP/p300. EMBO J 1999; 18:1905-1914. (Pubitemid 29158534)
82. Brusselmanns K, Bono F, Maxwell PH et al. Hypoxia-inducible factor-2 is involved in the apoptotic response to hypoglycemia but not to hypoxia. J Biol Chem 2001; 276:39192-39196.
83. Ryan HE, Lo J, Johnson RS. HIF-1 is required for solid tumor formation and embryonic vascularization. EMBO J 1998; 17(11):3005-15. (Pubitemid 28254373)
84. Tian H, Hammer RE, Matsumoto AM et al. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 1998; 12(21):3320-4. (Pubitemid 28520979)
85. Smaldone MC, Maranchie JK. Clinical implications in hypoxia inducible factor in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 2009; 27:238-245.
86. Holmquist L, Jogi A, Pahlman S. Phenotypic persistence after reoxygenation of hypoxic neuroblastoma cells. Int J Cancer 2005; 116(2):218-25. (Pubitemid 40967258)
87. Koshiji M, Kageyama Y, Pete EA et al. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 2004; 23:1949-1956. (Pubitemid 38902073)
88. Gordan JD, Bertout JA, Hu CJ et al. HIF-2alpha Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional Activity. Cancer Cell 2007a; 11:335-347. (Pubitemid 46518312)
89. Mandriota SJ, Turner KJ, Davies DR et al. HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002; 1:459-468. (Pubitemid 41039126)
90. Raval RR, Lau KW, Tran MG et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau associated renal cell carcinoma. Mol Cell Biol 2005; 25:5675-5686. (Pubitemid 40853601)
91. Wiesener MS, Jurgensen JS, Rosenberger C et al. Widespread hypoxia-inducible expression of HIF-2 in distinct cell populations of different organs. FASEB J 2003; 17(2):271-3.
92. Mandriota SJ, Turner KJ, Davies DR et al. HIF activation identifies early lesions in VHL kidneys. Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002; 1(5):459-68. (Pubitemid 41039126)
93. Kim CM, Vocke C, Torres-Cabala C et al. Expression of hypoxia inducible factor-1 and 2 in genetically distinct early renal cortical tumors. J Urol 2006; 175(5):1908-14.
94. Kondo K, Klco J, Nakamura E et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002; 1:237-246. (Pubitemid 41039148)
95. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008; 319:1352-1355. (Pubitemid 351354863)
96. Hook SS, Lin JJ, Dutta A. Mechanisms to control rereplication and implications for cancer. Curr Opin Cell Biol 2007; 19:663-671. (Pubitemid 350216429)
97. Lee AC, Fenster BE, Ito H et al. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem 1999; 274:7936-7940.
98. Bartkova J, Horejsi Z, Koed K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434:864-87.
99. Gorgoulis VG, Vassiliou LV, Karakaidos P et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434:907-913. (Pubitemid 40559004)
100. Ray S, Atkuri KR, Deb-Basu D et al. MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Res 2006; 66:6598-6605. (Pubitemid 44085615)
101. Vafa O, Wade M, Kern S et al. c-Myc can induce DNAvdamage, increase reactive oxygen species and mitigate p53 function: A mechanism for oncogeneinduced genetic instability. Mol Cell 2002; 9:1031-1044. (Pubitemid 34626672)
102. Koshiji M, To KK, Hammer S et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell 2005; 17:793-803. (Pubitemid 40386941)
103. Gordan JD, Lal P, Dondeti VR et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. 2008; 14(6):435-46.
104. Maranchie JK et al. The contribution of VHL substrate binding and HIF1+ to the phenotype of VHL Loss in renal cell carcinoma. Cancer Cell 2002; 1:247-255. (Pubitemid 41039149)
105. Gu YZ, Moran SM, Hogenesch JB et al. Molecular characterization and chromosomal localization of a third-class hypoxia inducible factor subunit, HIF3. Gene Expr 1998; 7(3):205-13. (Pubitemid 28527216)
106. Maynard MA, Qi H, Chung J et al. Multiple splice variants of the human HIF-3 locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 2003; 278(13):11032-40. (Pubitemid 36792653)
107. Maynard MA, Evans AJ, Hosomi T et al. Human HIF-3-4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma. FASEB J 2005; 19(11):1396-406. (Pubitemid 41278998)
108. Esteban MA, Tran MG, Harten SK et al. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 2006; 66:3567-3575.
109. Evans AJ, Russell RC, Roche O et al. VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol 2007; 27:157-169. (Pubitemid 46013241)
110. Krishnamachary B, Zagzag D, Nagasawa H et al. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor null renal cell carcinoma mediated by TCF3, ZFHX1A and ZFHX1B. Cancer Res 2006; 66:2725-2731.
111. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin and cadherin pathways. Science 2004; 303:1483-1487. (Pubitemid 38314410)
112. Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006; 16:51-59. (Pubitemid 43089612)
113. Nakaigawa N, Yao M, Baba M et al. Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. Cancer Res 2006; 66:3699-3705.
114. Peruzzi B, Athauda G, Bottaro DP. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc Natl Acad Sci USA 2006; 103:14531-14536. (Pubitemid 44484784)
115. Drees F, Pokutta S, Yamada S et al.β-Catenin is a molecular switch that binds E-cadherin-catenin and regulates actin-filament assembly. Cell 2005; 123:903-915. (Pubitemid 41721035)
116. Yamada S, Pokutta S, Drees F et al. Deconstructing the cadherin-catenin-actin Complex. Cell 2005; 123:889-901. (Pubitemid 41721034)
117. Behrens J, von Kries JP, Kuhl M et al. Functional interaction of -catenin with the transcription factor LEF-1. Nature 1996; 382:638-642. (Pubitemid 26268958)
118. Huber O, Korn R, McLaughlin J et al. Nuclear localization of -catenin by interaction with transcription factor LEF-1. Mech Dev 1996; 59:3-10. (Pubitemid 26325455)
119. Thoma CR, Frew IJ, Hoerner CR et al. pVHL and GSK3-beta are components of a primary cilium-maintenance signalling network. Nat Cell Biol 2007; 9:588-595. (Pubitemid 46696541)
120. Schermer B, Ghenoiu C, Bartram M et al. The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth. J Cell Biol 2006; 175:547-554. (Pubitemid 44790608)
121. Esteban MA, Harten SK, Tran MG et al. Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein. J Am Soc Nephrol 2006; 17:1801-1806. (Pubitemid 44036164)
122. Lutz MS, Burk RD. Primary cilium formation requires von hippel-lindau gene function in renal-derived cells. Cancer Res 2006; 66:6903-6907. (Pubitemid 44197663)
123. Ohh M, Yauch RL, Lonergan KM et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998; 1:959-968. (Pubitemid 128379257)
124. Tang N, Mack F, Haase VH et al. pVHL Function is essential for endothelial extracellular matrix deposition. Mol And Cell Biol 2006; 26(7):2519-2530.
125. Clifford SC, Cockman ME, Smallwood AC et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 2001; 10:1029-1038. (Pubitemid 32447780)
126. Hoffman MA, Ohh M, Yang H et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 2001; 10:1019-1027. (Pubitemid 32447779)
127. Stickle NH, Chung J, Klco JM et al. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol 2004; 24:3251-3261. (Pubitemid 38452070)
128. Kurban G, Hudon V, Duplan E et al. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion and angiogenesis. Cancer Res 2006; 66:1313-1319. (Pubitemid 43259909)
129. Grosfeld A, Stolze IP, Cockman ME et al. Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressor. J Biol Chem 2007; 282:13264-13269. (Pubitemid 47100504)
130. Kurban G, Duplan E, Ramlal N et al. Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2. Oncogene 2008; 27:1004-1012. (Pubitemid 351225387)
131. Roe JS, Kim HS, Lee SM et al. p53 stabilization and transactivation by von Hippel-Lindau protein. Mol Cell 2006; 22:395-405.
132. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: The molecular basis for p53 regulation. Curr Opin Cell Biol 2003; 15:164-71. (Pubitemid 36332191)
133. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303. (Pubitemid 27220767)
134. Sakaguchi K, Herrera JE, Saito S et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 1998; 12:2831-41. (Pubitemid 28440142)
135. Maher ER, Yates JR, Harries R et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990; 77(283):1151-1163. (Pubitemid 20379533)
136. Couch V, Lindor MS, Noralane M et al. von Hippel-Lindau disease. Mayo Clin Proc 2000; 75:265-272. (Pubitemid 30134156)
137. Kaelin WG. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007; 13:680s-684s.
138. Weirich G, Klein B, Wohl T et al. VHL2C phenotype in a German von Hippel-Lindau family with concurrent VHL germline mutations P81S and L188V. J Clin Endoc Metab 2002; 87:5241-5246. (Pubitemid 35316370)
139. Hes F, Zewald R, Peeters T et al. Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene. Hum Genet 2000; 106:425-31. (Pubitemid 30237510)
140. Lamiell JM, Salazar FG, Hsia YE. Von Hippl-Lindau disease affecting 43 members of a single kindred. Medicine 1989; 68:1-29. (Pubitemid 19041250)
141. Lonser RR, Glenn GM, Walther M et al. Von Hippel Lindau disease. Lancet 2003; 361:2059-2067.
142. Wanebo JE, Lonser RR, Glenn GM et al. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg 2003; 98:82-94. (Pubitemid 36050451)
143. Neumann HP, Eggert HR, Scheremet R et al. Central nervous system lesions in von Hippel-Lindau syndrome. J Neurol Neurosurg Psychiatry 1992; 55:898-901.
144. Filling-Katz MR, Choyke PL, Oldfield E et al. Central nervous system involvement in Von Hippel-Lindau disease. Neurology 1991; 41:41-46.
145. Choyke PL, Glenn GM, Walther MM et al. Von Hippel-Lindau disease: Genetic, clinical and imaging features. Radiology 1995; 194:629-642.
146. Torreggiani WC, Keogh C et al. Von Hippel-Lindau disease: A radiological essay. Clin Radiol 2002; 57:670-680.
147. Pavesi G, Feletti A, Berlucchi S et al. Neurosurgical treatment of von Hippel-Lindau-associated hemangioblastomas: Benefits, risks and outcome. J Neurosurg Sci 2008; 52:29-36.
148. Lonser RR, Weil RJ, Wanebo JE et al. Surgical management of spinal cord hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg 2003; 98:106-116. (Pubitemid 36050453)
149. Weil RJ, Lonser RR, DeVroom HL et al. Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg 2003; 98:95-105. (Pubitemid 36050452)
150. Niemela M, Lim YJ, Soderman M et al. Gamma knife radiosurgery in 11 hemangioblastomas. J Neurosurg 1996; 85:591-96. (Pubitemid 26315191)
151. Page KA, Wayson K, Steinberg GK et al. Stereotaxic radiosurgical ablation: An alternative treatment for recurrent and multifocal hemangioblastomas: A report of four cases. Surg Neurol 1993; 40:424-28. (Pubitemid 23314213)
152. Patrice SJ, Sneed PK, Flickinger JC et al. Radiosurgery for hemangioblastoma: Results of a multi-institutional experience. Int J Radiat Oncol Biol Phys 1996; 35:493-99. (Pubitemid 26242897)
153. Chang SD, Meisel JA, Hancock SL et al. Treatment of hemangioblastomas in von Hippel-Lindau disease with linear accelerator-based radiosurgery. Neurosurgery 1998; 43:28-34.
154. Dollfus H, Massin P, Taupin P et al. Retinal hemangioblastoma in von Hippel-Lindau disease: A clinical and molecular study. Invest Ophthalmol Vis Sci 2002; 43:3067-74. (Pubitemid 34977061)
155. Webster AR, Maher ER, Moore AT. Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation. Arch Ophthalmol 1999; 117:371-78. (Pubitemid 29133733)
156. Oosterhuis JA, Rubinstein K. Hemangioma at the optic disc. Ophthalmologica 1972; 164:362-374.
157. Singh AD, Nouri M, Shields CL et al. Treatment of retinal capillary hemangioma. Ophthalmology 2002; 109:1799-1806.
158. Manski TJ, Heffner DK, Glenn GM et al. Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau Disease. JAMA 1997; 277:1461-1466. (Pubitemid 27208889)
159. Luff DA, Simmons M, Malik T et al. Pathology in Focus. Endolymphatic sac tumours. J of Laryngology and Otology 2002; 116:398-401. (Pubitemid 34454533)
160. Meister M, Choyke P, Anderson C et al. Radiological evaluation, management and surveillance of renal masses in von Hippel-Lindau disease. Clinical Radiology 2009; 64:589-600.
161. Solomon D, Schwartz A. Renal pathology in von Hippel-Lindau disease. Hum Pathol 1988; 19:1072-1079.
162. Lamiell JM, Salazar FG, Hsia YE. von Hippel-Lindau disease affecting 43 members of a single kindred 1989; 68(1):1-29.
163. Neumann HP, Bender BU, Berger DP et al. Prevalence, morphology and
164. Walther MM, Choyke PL, Glenn G et al. Renal cancer in families with hereditary renal cancer: Prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol 2001; 161:1475-1479. (Pubitemid 29420799)
165. Poston CD, Jaffe GS, Lubensky IA et al. Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: Clinical and molecular genetic implications. J Urol 1995; 153:22-26. (Pubitemid 24379788)
166. Pavlovich CP, Walther MM, Choyke PL et al. Percutaneous radio frequency ablation of small renal tumours: Initial results. J Urol 2002; 167:10-15. (Pubitemid 34024484)
167. Shingleton WB, Sewell PE Jr. Percutaneous renal tumour cryoablation with magnetic resonance imaging guidance. J Urol 2001; 165:773-776. (Pubitemid 32156274)
168. Gill IS, Novick AC, Meraney AM et al. Laparoscopic renal cryoablation in 32 patients. Urology 2000; 56:748-753.
169. Gill IS, Remer EM, Hasan WA et al. Renal cryoablation: Outcome at 3 years. J Urol 2005; 173:1903-1907. (Pubitemid 40675207)
170. Hafron J, Kaouk JH. Ablative techniques for the management of kidney cancer. Nat Clin Pract 2007; 4:261-269. (Pubitemid 46745487)
171. Chauveau D, Duvic C, Chretien Y et al. Renal involvement in von Hippel-Lindau disease. Kidney Int 1996; 50:944-951. (Pubitemid 26302684)
172. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342. (Pubitemid 38702844)
173. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med 2006; 355:2542-2550. (Pubitemid 44917502)
174. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Eng J Med 2007; 357:2666-2676.
175. Kim JJ, Rini BI. Recent advances in molecularly targeted therapy in advanced renal cell carcinoma. Therapy 2009; 6(3):309-320.
176. Aiello LP, George DJ, Cahill MT et al. Rapid durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor SU5416. Amer Acad Opth 2002; 109(9):1745-1751. (Pubitemid 35006409)
177. Walther MM, Reiter R, Keiser HR et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: Comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 1999; 162:659-664. (Pubitemid 29436843)
178. Weise M, Merke DP, Pacak K et al. Utility of plasma free metanephrines for detecting childhood pheochromocytoma. J Clin Endocrinol Metab 2002; 87:1955-60. (Pubitemid 34521473)
179. Neumann HP, Berger DP, Sigmund G. Pheochromocytomas, multiple endocrine neoplasia Type 2 and von Hippel Lindau disease. N Engl J Med 329:1531-1538.
180. Eisenhofer G, Lenders JW, Linehan WM et al. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 1999; 340:1872-79. (Pubitemid 29272667)
181. Mugawar M, Rajender Y, Purohit AK et al. Anesthetic management of von Hippel-Lindau syndrome for excision of cerebellar hemangioblastoma and pheochromocytoma surgery. Anesth Analg 1998; 86:673-674. (Pubitemid 28119443)
182. Harrington JL, Farley DR, van Heerden JA et al. Adrenal tumors and pregnancy. World J Surg 1999; 23:182-186. (Pubitemid 29047377)
183. Lairmore TC, Ball DW, Baylin SB et al. Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. Ann Surg 1993; 217:595-601.
184. Pavlovich CP, Linehan WM, Walther MM. Partial adrenalectomy in patients with multiple adrenal tumours. Curr Urol Rep 2001; 2:19-23.
185. Baghai M, Thompson GB, Young WF Jr et al. Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: A role for laparoscopic and cortical-sparing surgery. Arch Surg 2002; 137:682-88.
186. Hammel PR, Vilgrain V, Terris B et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology 2000; 119:1087-1095.
187. Binkovitz LA, Johnson CD, Stephens DH. Islet cell tumors in von Hippel-Lindau disease: Increased prevalence and relationship to the multiple endocrine neoplasias. AJR Am J Roentgenol 1990; 155:501-505. (Pubitemid 20254489)
188. Libutti SK, Choyke PL, Bartlett DL et al. Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: Diagnostic and management recommendations. Surgery 1998; 124:1153-1159. (Pubitemid 28555208)
189. Gruber MB, Healey GB, Toguri AG et al. Papillary cystadenoma of epididymis: Component of von Hippel-Lindau syndrome. Urology 1980; 16:305-306. (Pubitemid 11195731)
190. Choyke PL, Glenn GM, Wagner JP et al. Epididymal cystadenomas in von Hippel-Lindau disease. Urology 1997; 49:926-31. (Pubitemid 27246964)
191. Funk KC, Heiken JP. Papillary cystadenoma of the broad ligament in a patient with von Hippel-Lindau disease. AJR Am J Roentgenol 1989; 153:527-558.